Parabiotic Research & Development Corp.

Parabiotic's focus is on the development of innovative combination antibiotic/probiotic drug products for the treatment of Inflammatory Bowel disease-ulcerative colitis and Crohn's disease. The company's patented lead product, PB-1, is the first of a new class of targeted combination drugs that will address underlying suspected causal factors in the initiation of disease- as opposed to being merely symptom managing.